Christopher Junge is the Director of Corporate Projects at Axmed. His passion for public health stems from recognizing how one’s life can be fundamentally influenced by the country and health system they are born into.
With 14 years in the pharmaceutical industry, Christopher has spent seven years at Sandoz in marketing and sales for Germany, and another seven years at Novartis. Sandoz, the generic arm of Novartis, provided him with a comprehensive view of the pharmaceutical landscape.
At Novartis, Christopher joined the Novartis Access team, which later became Novartis Global Health & Sustainability. He designed and implemented various programs leveraging Novartis’ expertise in drug research, development, and access to medicines to address health priorities in underserved regions.
In Ghana, he learned about sickle cell disease, a prevalent genetic disorder in Africa. He led the introduction of hydroxyurea, a life-saving drug, in partnership with the government to ensure its affordability.
His public health efforts continued with the Cancer Access Partnership (CAP), a collaboration between Novartis and the Clinton Health Access Initiative (CHAI), reducing cancer medicine costs in Sub-Saharan Africa by nearly 60%. He also led Novartis’ Global Health Avoidable Blindness program, addressing blindness in low- and middle-income countries through collaborations with major NGOs.
Christopher’s academic background includes a Bachelor’s in American Studies from the University of Leipzig and a semester in Business Administration at Ramkhamhaeng University in Bangkok. These experiences paved the way for his entry into the corporate world, starting with Sandoz in 2011.